- Home
- APLS
as 05-30-2025 4:00pm EST
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.2B | IPO Year: | 2017 |
| Target Price: | $37.50 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.10 - $43.76 | Next Earning Date: | 05-07-2025 |
| Revenue: | $775,839,000 | Revenue Growth: | 48.04% |
| Revenue Growth (this year): | 1.54% | Revenue Growth (next year): | 22.80% |
Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chopas James George | APLS | VP/Chief Accounting Officer | Mar 17 '25 | Sell | $24.82 | 183 | $4,542.74 | 47,955 | |
| Watson David O. | APLS | General Counsel | Mar 4 '25 | Sell | $25.10 | 5,569 | $139,789.14 | 138,730 |
Latest Apellis Pharmaceuticals Inc. News
APLS Breaking Stock News: Dive into APLS Ticker-Specific Updates for Smart Investing
MT Newswires
18 days ago
Mizuho Securities Adjusts Apellis Pharmaceuticals Price Target to $20 From $30, Maintains Neutral Rating
MT Newswires
22 days ago
Apellis Pharmaceuticals' Funding Gaps, Weak Syfovre Sales Cloud Outlook, BofA Says
TipRanks
22 days ago
Apellis price target lowered to $20 from $28 at Scotiabank
Investing.com
22 days ago
Apellis Pharmaceuticals downgraded by Raymond James due to ’added uncertainty’
Insider Monkey
22 days ago
Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back?
MT Newswires
23 days ago
Raymond James Downgrades Apellis Pharmaceuticals to Outperform From Strong Buy, Adjusts Price Target to $52 From $75
MT Newswires
23 days ago
BofA Securities Downgrades Apellis Pharmaceuticals to Neutral, Price Target is $23
Zacks
23 days ago
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
Compare APLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLS Apellis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.